PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
34.57%
Cash & equivalents yoy growth below half of AGEN's 76.08%. Michael Burry would question if the firm faces a liquidity squeeze. Check for rising debts or negative cash flow.
68.63%
Higher Short-Term Investments Growth compared to AGEN's zero value, indicating better performance.
34.59%
Below half of AGEN's 76.08%. Michael Burry might suspect a liquidity shortfall if there's no alternative capital plan.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
31.58%
Below half of AGEN's 71.79%. Michael Burry could suspect a liquidity squeeze. Verify operational performance.
-15.03%
Below half AGEN's 18.25%. Michael Burry sees potential underinvestment risk unless there's a valid reason (asset-light model).
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-11.19%
Below half of AGEN's 5.15%. Michael Burry might suspect stagnation or lack of resources for expansions.
No Data
No Data available this quarter, please select a different quarter.
31.29%
0.5-0.75x AGEN's 53.52%. Martin Whitman worries about slower asset growth than competitor. Is it strategy or constraint?
-18.99%
50-75% of AGEN's -32.99%. Bruce Berkowitz notes the company is paying suppliers faster or not stretching terms as competitor does.
-51.38%
Similar yoy changes to AGEN's -65.54%. Walter Schloss finds a parallel approach to short-term funding.
No Data
No Data available this quarter, please select a different quarter.
-91.88%
≥ 1.5x AGEN's -18.88%. David Dodd sees stronger subscription/prepayment demand.
-10.37%
Less than half of AGEN's 31.30%. David Dodd sees fewer expansions in other current obligations.
-15.50%
Less than half of AGEN's 20.58%. David Dodd sees a more disciplined short-term liability approach.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-15.50%
Less than half of AGEN's 30.75%. David Dodd sees far fewer liability expansions relative to competitor.
13.39%
50-75% of AGEN's 18.95%. Bruce Berkowitz notes minimal new equity relative to competitor.
-7.92%
1.25-1.5x AGEN's -5.69%. Bruce Berkowitz notes stronger reinvestment strategy.
-32.48%
Less than half of AGEN's 45.41%. David Dodd sees fewer intangible or market-driven swings than competitor.
No Data
No Data available this quarter, please select a different quarter.
41.56%
Below half AGEN's 88.48%. Michael Burry sees potential underperformance in building shareholder capital.
31.29%
0.5-0.75x AGEN's 53.52%. Martin Whitman sees underexpansion or possible missed opportunities.
68.63%
Higher Total Investments Growth compared to AGEN's zero value, indicating better performance.
-51.38%
Above 1.5x AGEN's -0.65%. Michael Burry sees a major jump. Investigate leverage rationale.
-35.43%
Less than half of AGEN's -89.10%. David Dodd sees better deleveraging or stronger cash buildup than competitor.